Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures sink as AI doubts resurface, oil jumps
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Vericel (VCEL) Misses Q1 EPS by 3c, Revenues Beat; Raises FY21 Revenues Guidance Above Consensus
May 5, 2021 7:11 AM EDTVericel (NASDAQ: VCEL) reported Q1 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $34.06 million versus the consensus estimate of $32.05 million.
First Quarter 2021 Financial Highlights
Total net revenue increased 30% to $34.6 million, compared to $26.7 million in the first quarter of 2020MACI® net revenue of $23.8 million, Epicel® net revenue of $9.8 million and NexoBrid® revenue of $0.9 million related to the U.S. Biomedical Advanced Research and Development Authority (BARDA)... More


